Cagrilintide vs Semaglutide: How the Two Compare

Cagrilintide and semaglutide are two of the most studied long-acting peptides in metabolic signaling research. They are often named together, yet they act on different receptor systems. This comparison of cagrilintide vs semaglutide covers what each compound is, which receptors it engages, how its structure extends persistence, and why labs study the two side by side. Both are research-use-only materials.

What is the difference between cagrilintide and semaglutide?

Cagrilintide is a long-acting amylin analog, while semaglutide is a long-acting GLP-1 receptor agonist. They are based on two different native hormones and engage two separate receptor families.

Amylin is a peptide hormone released together with insulin from pancreatic beta cells. Cagrilintide is a synthetic analog of amylin. It is engineered to persist far longer than the native hormone in experimental systems.

Semaglutide is a synthetic analog of glucagon-like peptide-1, or GLP-1. GLP-1 is an incretin, a gut-derived hormone tied to glucose-dependent signaling. Semaglutide carries amino acid substitutions relative to human GLP-1. It is one of the most referenced GLP-1 receptor agonists in the literature.

• Native hormone basis: amylin for cagrilintide, GLP-1 for semaglutide.
• Molecular class: long-acting amylin analog versus long-acting GLP-1 receptor agonist.
• Molecular weight: about 4409.01 g/mol versus about 4113.6 g/mol.
• Duration strategy: both rely on acylation and albumin binding.

What is cagrilintide?

Cagrilintide is a synthetic, acylated amylin analog studied as a non-selective agonist at amylin and calcitonin receptors. Its CAS number is 1415456-99-3 and its formula is C194H312N54O59S2. Synonyms in the literature include AM833 and NNC0174-0833.

Native amylin is short-lived, which limits how long it can drive receptor signaling in vitro. Cagrilintide was designed to close that gap. Researchers use it to study sustained amylinergic signaling, meaning signaling through amylin receptors, that the native peptide cannot hold. It is also used in comparative work that contrasts native amylin, short-acting analogs, and long-acting designs. The cagrilintide mechanism of action article walks through the receptor biology in more detail.

Semaglutide, for its part, has CAS number 910463-68-2 and formula C187H291N45O59. Its synonyms include NNC 0113-0217.

Which receptors do cagrilintide and semaglutide target?

Cagrilintide targets the amylin and calcitonin receptor family, while semaglutide targets a single receptor, GLP-1R.

Amylin receptors are not one protein. They form when the calcitonin receptor, CTR, pairs with a receptor activity-modifying protein, called a RAMP. Different RAMP pairings give different amylin receptor subtypes. Cagrilintide is investigated as an agonist across these subtypes and at the calcitonin receptor itself.

Semaglutide is studied as a selective GLP-1 receptor agonist. In receptor-expressing cells, GLP-1R activation is associated with cAMP-mediated signaling. Because it engages one receptor, semaglutide gives a clean reference point for isolating GLP-1R responses. The semaglutide mechanism of action article covers that pathway. The retatrutide vs tirzepatide vs semaglutide comparison shows how it serves as a benchmark for multi-receptor peptides.

How do acylation and albumin binding compare?

Both compounds use the same general strategy for persistence: a fatty-acid chain that binds albumin reversibly.

Acylation means attaching a fatty-acid chain to the peptide. Serum albumin, the most abundant blood protein, has binding sites for fatty acids. When an acylated peptide binds albumin reversibly, it is shielded from rapid clearance and enzymatic breakdown in experimental systems.

Semaglutide carries a C18 fatty diacid side chain attached through a linker. The literature associates this with reversible albumin binding and greater resistance to enzymatic degradation. Cagrilintide carries its own lipidation modification for the same purpose. In both cases, the effect studied in models is prolonged stability and sustained receptor engagement.

This shared design matters for study planning. Because both compounds persist over a similar long window, they can be engaged in parallel without one input fading well before the other.

Why are semaglutide and cagrilintide studied together?

Semaglutide and cagrilintide are studied together because they engage two separate receptor systems that both feed into metabolic signaling.

The pairing appears in the literature under the research designation CagriSema. The research question is how amylinergic and incretin signaling behave when both are engaged at once. A second question is how combined signaling compares with either pathway alone. In animal energy-balance models, this is studied as a possible complementary interaction, not an established outcome.

For labs running that design, Puritide Research supplies a pre-mixed Cagrilintide+Semaglutide research blend at 5 mg of each peptide per vial. It removes one weighing step and one source of ratio error. Studies that need single-agonist control arms or a different ratio are better served by separate vials.

Which compound fits which research question?

The choice follows from the receptor system the question is about.

• Amylin or calcitonin receptor pharmacology, RAMP-dependent subtypes, or sustained amylinergic signaling: cagrilintide, supplied as a 10 mg vial.
• GLP-1 receptor activation, cAMP signaling, or a single-receptor benchmark for dual and tri-receptor peptides: semaglutide, supplied in 10, 20, and 30 mg vials.
• Combined amylin and incretin signaling: the blend, run next to single-compound arms so each contribution can be traced.
• Native versus long-acting amylin designs: cagrilintide, with native amylin as the reference.

The two compounds are not interchangeable. Swapping one for the other changes the receptor under study, so the data would no longer answer the original question.

How are cagrilintide and semaglutide handled in the lab?

Both ship as a solid white lyophilized powder in a sealed glass vial and share the same storage guidance.

• Store sealed at or below 25 degrees Celsius, away from heat, light, and moisture.
• For extended storage, keep the material lyophilized and refrigerated or frozen.
• Keep reconstituted peptide refrigerated and use it within the window your lab's SOP sets.
• Record lot numbers, storage conditions, and handling steps for each compound.

Every batch comes with a third-party certificate of analysis covering HPLC purity and mass-spectrometry identity. For the blend, identity is confirmed for both components. Puritide Research sources and independently tests these materials. It does not make them in-house. The two powders look the same, so mass spectrometry, not appearance, is how identity is confirmed.

For research use only. Cagrilintide and semaglutide are laboratory research compounds supplied for in vitro and preclinical investigation. Neither is supplied for human or veterinary use, and nothing above is medical guidance or a description of outcomes in people.